RxDoctor Payments Data

Danielle Bennett, DO

Family Medicine · Bay City, MINPI 1881717528

Payments from drug & device makers

$619in general payments, 2019–2025

Across 17 payments — averaging $36.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$118
  • AbbVie$115
  • Cochlear Americas$94
  • Lilly USA, LLC$84
  • GSK$64
  • Baxter Healthcare$36
  • plus $108 from 5 others

What the payments were for

  • Food & beverage$619100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$619 in reported general payments places this provider in the 60th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$36,477
Medicare patients
130
Services billed
444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide117$157,871
EliquisApixaban71$64,024
RybelsusSemaglutide38$57,385
FarxigaDapagliflozin Propanediol36$43,485
TrulicityDulaglutide28$43,346
WegovySemaglutide16$27,512
MounjaroTirzepatide15$25,073
Tadalafil11$24,961
JardianceEmpagliflozin14$20,132
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$15,704
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$10,781
Aimovig AutoinjectorErenumab-Aooe11$9,627
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$5,275
Incruse ElliptaUmeclidinium Bromide12$4,354
Methylphenidate ErMethylphenidate Hcl11$4,100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$118$242,768171 claims
Lilly USA, LLCTrulicity, Mounjaro$84$68,41943 claims
AstraZenecaFarxiga$28$43,48536 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$64$30,83946 claims
AbbVieSynthroid$115$2,30732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Bay City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →